111. 先天性ミオパチー Congenital myopathy Clinical trials / Disease details

臨床試験数 : 10 / 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 9

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-000876-27-DE (EUCTR)	22/05/2018	22/09/2017	First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) Patients	ASPIRO: A Phase 1/2/3, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control ...	X-linked Myotubular Myopathy (XLMTM) MedDRA version: 20.0;Level: HLGT;Classification code 10029317;T ...	Product Name: rAAV8-Des-hMTM1 Product Code: AT132	Audentes Therapeutics Inc.	NULL	Not Recruiting			Female: no Male: yes	26	Phase 1;Phase 2	France;United States;Canada;Germany;United Kingdom
2	EUCTR2017-000876-27-FR (EUCTR)	23/04/2018	25/05/2018	First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) Patients	ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Cl ...	X-linked Myotubular Myopathy (XLMTM);Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] ...	Product Name: rAAV8-Des-hMTM1 Product Code: AT132	Audentes Therapeutics Inc.	NULL	Not Recruiting			Female: no Male: yes	12	Phase 1;Phase 2	United States;France;Germany;United Kingdom
3	EUCTR2017-000876-27-GB (EUCTR)	06/12/2017	31/07/2017	First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) Patients	ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Cl ...	X-linked Myotubular Myopathy (XLMTM);Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] ...	Product Name: rAAV8-Des-hMTM1 Product Code: AT132	Audentes Therapeutics Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	20	Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ...	France;United States;Germany;United Kingdom

First Previous1Next Last